Alpha-glucosidase inhibitors

Alpha-glucosidase inhibitors has been studied in 41 papers since 2005: 1 trial and 17 observational studies in people, 21 reviews; 17 in the past year. The newest story, Oct 26, 2026: “Several diabetes drugs are linked to lower aortic aneurysm risk”.

Intervention

41 papers study it13 findingsUpdated

6 new papers in 30 daysSee all 41 papers on alpha-glucosidase inhibitors

At a glance

The findings reach people, from one lab or study. 6 independent labs in 2 countries.

“α-glucosidase inhibitors (aHR 0.83, 95% CI 0.77 - 0.89) were associated with lower AA risk.”
Associations between Antidiabetic Drug Classes and Aortic Aneurysm Risk in Patients with Type 2 Diabetes: A Nationwide Cohort StudyEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery2026doi:10.1016/j.ejvs.2026.11.015

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 6 independent labs in 2 countries
  • Funders: Medical Science and Technology Project of Zhejiang Province and others
  • Human trial1
  • Humans17
  • In silico1

Studies in people

1 study gave alpha-glucosidase inhibitors to people and measured what changed.

What changedDesignPeopleSource

down: Decreases postprandial blood glucose incrementsum postprandial glucose increments differed by agent, P = .03; interaction P = .04

Randomized trial21 peopleIn patients whose abdominal symptoms were caused by the drug; treatment-by-symptom interactionMetabolism: clinical and experimental, Mar 1, 2005

What did studies of alpha-glucosidase inhibitors find?

4

Studies of alpha-glucosidase inhibitors measured 4 outcomes, among them iron, lifespan and blood glucose.

Iron

downin humans1

1 study
  1. Alpha-glucosidase inhibitors are linked with lower iron in humans (type 2 diabetes).

    “And AGI reduces serum iron levels, both before (p = 0.01) and after PSM (p = 0.028).”

    Humanstype 2 diabetes

    Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes

    Scientific reports

More on Iron

Lifespan

upin reviews1

1 study
  1. Alpha-glucosidase inhibitors extend lifespan.

    “AGIs have shown potential in extending lifespan and effectively treating aging-related diseases”

    Review

    Alpha-Glucosidase Inhibitors in Aging and Aging-Related Diseases: Clinical Applications and Relevant Mechanisms

    Aging and disease

Blood glucose

downin reviews1

1 study
  1. Alpha-glucosidase inhibitors decrease blood glucose.

    “AGIs act by altering the intestinal absorption of carbohydrates through inhibition of their conversion into simple sugars (monosaccharides) and thus decrease the bioavailability of carbohydrates in the body, significantly lowering blood glucose levels.”

    Review

    Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes

    Open heart

More on Blood glucose

Postprandial blood glucose increment

downin humans1

1 study
  1. Alpha-glucosidase inhibitors decrease postprandial blood glucose increment in humans (sum postprandial glucose increments differed by agent, P = .03; interaction P = .04).

    “with favorable efficacy in patients in whom the alpha-glucosidase inhibitor caused abdominal symptoms”

    Human trialin patients whose abdominal symptoms were caused by the drug; treatment-by-symptom interactionn = 21

    Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms

    Metabolism: clinical and experimental

More on Postprandial blood glucose increment

What is alpha-glucosidase inhibitors linked with?

8

Studies link alpha-glucosidase inhibitors with 8 measures, among them glycemic control, aortic aneurysm and sarcopenia.

Glycemic control

no changein humans1

1 study
  1. Alpha-glucosidase inhibitors are associated with glycemic control in humans (diabetes undergoing extended-hours hemodialysis with a liberalized diet) (average glycated albumin 18.0±1.7%).

    “In this case, monotherapy with α-glucosidase inhibitors maintained glycemic control, with an average glycated albumin level of 18.0±1.7%.”

    Humansdiabetes undergoing extended-hours hemodialysis with a liberalized dietmonotherapyfemales

    Twenty-Three Years of Survival Observed in a Diabetic Woman Receiving Extended-Hours Hemodialysis (18-25 Hours per Week) With a Liberalized Diet

    Journal of medical cases

Aortic aneurysm

downin humans1

1 study
  1. Alpha-glucosidase inhibitors are associated with aortic aneurysm in humans (type 2 diabetes mellitus) (aHR 0.83, 95% CI 0.77–0.89).

    “α-glucosidase inhibitors (aHR 0.83, 95% CI 0.77 - 0.89) were associated with lower AA risk.”

    Humanstype 2 diabetes mellitus8.5 ± 4.7 years52.8% mensn = 3,295,564

    Associations between Antidiabetic Drug Classes and Aortic Aneurysm Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study

    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

More on Aortic aneurysm

Sarcopenia

upin humans1OR 4.376

1 study
  1. Alpha-glucosidase inhibitors are associated with sarcopenia in humans (Medication use in community-dwelling men receiving chronic disease management) (OR = 4.376).

    “α-glucosidase inhibitors (AGIs) use (OR = 4.376)”

    HumansMedication use in community-dwelling men receiving chronic disease managementmalesn = 172

    Gut microbiota dysbiosis and clinical correlates of sarcopenia in community-dwelling oldest-old men: a cross-sectional study

    BMC geriatrics

More on Sarcopenia

Chronic pruritus

upin humans1OR 1.272

1 study
  1. Alpha-glucosidase inhibitors are associated with chronic pruritus in humans (type 2 diabetes mellitus; adjusted for potential confounding factors) (adjusted OR 1.272, 95% CI 1.050–1.541).

    “CP in patients with T2DM was associated with the use of AGIs, DPP-4is, and statins.”

    Humanstype 2 diabetes mellitus; adjusted for potential confounding factorsn = 2,059

    The effect of medication use on chronic pruritus in patients with type 2 diabetes mellitus: a multicenter cross-sectional study

    Scientific reports

More on Chronic pruritus

FRAX score

upin humans1

1 study
  1. Alpha-glucosidase inhibitors are associated with FRAX score in humans (Chinese patients with type 2 diabetes mellitus; AGIs group versus non-AGIs group).

    “FRAX score and the prevalence of osteoporosis were remarkably increased”

    HumansChinese patients with type 2 diabetes mellitus; AGIs group versus non-AGIs groupn = 251

    Relationship Between α-Glucosidase Inhibitors Application and Bone Mineral Density in Chinese Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

    Diabetes, metabolic syndrome and obesity : targets and therapy

More on FRAX score

Osteoporosis prevalence

upin humans1

1 study
  1. Alpha-glucosidase inhibitors are associated with osteoporosis prevalence in humans (Chinese patients with type 2 diabetes mellitus; AGIs group versus non-AGIs group).

    “FRAX score and the prevalence of osteoporosis were remarkably increased”

    HumansChinese patients with type 2 diabetes mellitus; AGIs group versus non-AGIs groupn = 251

    Relationship Between α-Glucosidase Inhibitors Application and Bone Mineral Density in Chinese Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

    Diabetes, metabolic syndrome and obesity : targets and therapy

More on Osteoporosis prevalence

Lumbar spine bone mineral density

downin humans1

1 study
  1. Alpha-glucosidase inhibitors are associated with lumbar spine bone mineral density in humans (β = -0.053, 95% CI -0.100~0.006, P = 0.029).

    “Multivariate linear regression analysis showed a significant negative correlation between AGIs and lumbar BMD after adjustment for potential confounding variables”

    HumansChinese patients with type 2 diabetes mellitus; adjusted for potential confounding variableslumbar spinen = 251

    Relationship Between α-Glucosidase Inhibitors Application and Bone Mineral Density in Chinese Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

    Diabetes, metabolic syndrome and obesity : targets and therapy

More on Lumbar spine bone mineral density

Colorectal adenoma

downin humans1OR 0.399

1 study
  1. Alpha-glucosidase inhibitors are linked with a lower risk of colorectal adenoma in humans (type 2 diabetes) (OR 0.399, 95% CI 0.22-0.723).

    “Multivariate logistic regression analysis revealed that the AGI (Alpha-glucosidase inhibitor) Group had an adjusted OR of 0.399 (95% CI = 0.22-0.723, p = 0.002)”

    Humanstype 2 diabetesn = 311

    Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes

    Scientific reports

More on Colorectal adenoma

Latest

Dec 2025: 0Jan 2026: 2Feb 2026: 0Mar 2026: 3Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 2Sep 2026: 3Oct 2026: 2Nov 2026: 417 papers in 12 months
ESC Congress 2026 Abstract

Several diabetes drugs are linked to lower aortic aneurysm risk

In 3,432,327 adults with type 2 diabetes followed for a mean of 9.2 years, six medication categories were associated with a lower risk of aortic aneurysm.In 3,432,327 adults with type 2 diabetes followed for a mean of 9.2 years, six medication categories were associated with a lower risk of aortic aneurysm.

Cohort · 3,432,327 peopleAortic aneurysm

See all 41 papers on alpha-glucosidase inhibitors